Open AccessControlled‐Release Doxazosin as Combination Therapy in Hypertension: The GATES Study
Author(s) -
Black Henry R.,
Keck Michael,
Meredith Peter,
Bullen Kevin,
Quinn Sheila,
Koren Andrew
Publication year - 2006
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2006.04811.x
Subject(s) - doxazosin , medicine , placebo , blood pressure , urology , adverse effect , anesthesia , alternative medicine , pathology
Doxazosin gastrointestinal therapeutic system (GITS) or placebo was added to the antihypertensive therapy of uncontrolled hypertensive patients in a prospective, randomized, double‐blind trial. Patients received doxazosin GITS 4 mg/d (n=89) or placebo (n=86) for 6 weeks in addition to entry antihypertensive medication. Doxazosin GITS was increased to 8 mg/d after 2 or 4 weeks if patients did not respond (sitting blood pressure <140/90 mm Hg and 10/10‐mm Hg decrease from baseline). Reductions from baseline in sitting and standing blood pressures were greater with doxazosin GITS than placebo at all time points ( p ≤0.017) except Week 1 sitting systolic pressure ( p =0.068). The response rate was greater in the doxazosin GITS group (37.3%) than the placebo group (10.7%; p <0.001). With the exception of postural hypotension (7% compared with 0.0%), the frequency of adverse events was similar for doxazosin GITS and placebo. Doxazosin GITS was effective as combination antihypertensive therapy with the major classes of antihypertensive agents.